1 citations
,
November 2024 in “Blood” PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.
28 citations
,
January 2005 in “PubMed” Topical immunomodulators are effective and safe for treating immune-related skin conditions.
12 citations
,
March 2021 in “JAAD Case Reports” Nail changes from immunotherapy can be managed without stopping cancer treatment.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” PPARγ signaling modulation can protect hair follicle stem cells from chemotherapy-induced damage.
18 citations
,
October 2015 in “Journal of the European Academy of Dermatology and Venereology” Topical eflornithine helps maintain hair reduction after IPL therapy in women with facial hirsutism.
August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
November 2016 in “The Molecular Biology Society of Japan” 12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
June 2022 in “C&EN global enterprise” The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
4 citations
,
June 2024 in “British Journal of Dermatology” EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.
14 citations
,
November 2016 in “Lupus” Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.
April 2024 in “DAHUDER Medical journal” Ocrelizumab may cause pancreatitis in some patients.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
April 2023 in “Journal of Investigative Dermatology” Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
2 citations
,
October 2023 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
July 2022 in “British Journal of Dermatology”
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
January 2026 in “Clinical Cosmetic and Investigational Dermatology” Placenta polypeptide injection is a safe and effective treatment for sensitive skin.
January 2026 in “International Journal of Health Science” Human insulin via microinfusion may effectively improve atrophic acne scars.
1 citations
,
July 2021 in “Acta dermatovenerologica Croatica” Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
30 citations
,
March 2007 in “Expert opinion on drug safety” Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
3 citations
,
May 2019 in “Journal of Cosmetic Dermatology” Miliacin with polar lipids helps hair growth and improves hair loss in women.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.